| Co-Investigator(Kenkyū-buntansha) |
KOEDUKA Yasuhiko Kirin Brewery co., ltd., Pharmaceutical Research laboratories Oncology group, Senior Scientist, 薬理評価グループ, 主任研究員(研究職)
KAWASE Takeshi Keio University, School of Medicine, Professor, 医学部, 教授 (40095592)
KAWAKAMI Yutaka Keio University, School of Medicine, Professor, 医学部, 教授 (50161287)
|
|---|
| Research Abstract |
The central nervous system (CNS) has been considered to be an immunologically privileged site; however, recent evidence suggests that a series of immunological events can be initiated when the immune system recognizes CNS antigens. To develop a novel antigen-specific immunotherapy against glioma, we have attempted to identify tumor antigens using SEREX, serological identification of antigens by recombinant expression cloning. A total of 92 immunoreactive cDNA clones containing 52 different genes were isolated by screening of a cDNA library from glioma cell lines with 12 glioma patients' sera. We then evaluated the recognition of these antigens by sera from glioma patients, other brain disease patients, and normal individuals. Among 52 distinct antigens screened, we identified two previously uncharacterized cDNAs, KU-GB-1 and KU-GB-2, whose products were recognized only by sera from glioma patients. Gene expression analysis revealed that KU-GB-1 and KU-GB-2 were highly expressed in gliomas compared with normal tissues except testis. By further SEREX screening of a testis cDNA library with glioma patients' sera, three previously uncharacterized cDNAs, KU-GB-3, KU-GB-4, and KU-GB-5, were identified. These results indicate that proteins expressed in human glioma could be recognized by the immune system in the patients and may be utilized as targets for diagnosis and treatment of glioma.
|
